RxSight (RXST) Cash from Operations Growth (3y) (2023 - 2026)
RxSight (RXST) Cash from Operations Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 4.78% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 9.30% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 1.51% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 22.35% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -48.14% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 50.11% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 0.50% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | -14.75% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | RxSight | 221.81 Mn | -196.39 Mn | 23.50 Mn | 15.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.05% |
| Dec 31, 2025 | 56.81% |
| Sep 30, 2025 | 57.25% |
| Jun 30, 2025 | 33.41% |
| Mar 31, 2025 | 16.16% |
| Dec 31, 2024 | 21.25% |
| Sep 30, 2024 | 26.98% |
| Jun 30, 2024 | 30.47% |
| Mar 31, 2024 | 3.17% |
| Dec 31, 2023 | -0.30% |
| Sep 30, 2023 | -4.73% |